Eli Lilly每周一次的Insulin, efsitora alfa, 显示在两个阶段的3审判中, 与每日的Insulins相似的效力。 Eli Lilly's once-weekly insulin, efsitora alfa, demonstrated comparable efficacy to daily insulins in two Phase 3 trials.

Eli Lilly每周一次的Insulin(efsitora alfa)显示,在QWINT-1和QWINT-3两个阶段试验中,将血液糖含量降至每日的Insulins(QWINT-1和QWINT-3)的功效相当。 Eli Lilly's once-weekly insulin, efsitora alfa, has shown comparable efficacy in reducing blood sugar levels to daily insulins in two Phase 3 trials, QWINT-1 and QWINT-3. Efsitora在52周后A1C减少了1.31%,相当于每日胰岛素的1.27%。 Efsitora achieved a 1.31% reduction in A1C after 52 weeks, similar to 1.27% for daily insulin glargine. 安全情况相似,严重缺血症事件略有减少。 The safety profile was comparable, with slightly fewer severe hypoglycemia events. 宣布后莉莉的股票价格下跌2.25%。 The announcement led to a 2.25% drop in Lilly's stock price.